Cargando…

Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience

BACKGROUND: Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Yazawa, Takefumi, Hori, Tomohide, Yamamoto, Hidekazu, Harada, Hideki, Yamamoto, Michihiro, Yamada, Masahiro, Tani, Masaki, Sato, Asahi, Kamada, Yasuyuki, Tani, Ryotaro, Aoyama, Ryuhei, Sasaki, Yudai, Zaima, Masazumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667407/
https://www.ncbi.nlm.nih.gov/pubmed/33251035
http://dx.doi.org/10.4292/wjgpt.v11.i5.110
_version_ 1783610306573893632
author Yazawa, Takefumi
Hori, Tomohide
Yamamoto, Hidekazu
Harada, Hideki
Yamamoto, Michihiro
Yamada, Masahiro
Tani, Masaki
Sato, Asahi
Kamada, Yasuyuki
Tani, Ryotaro
Aoyama, Ryuhei
Sasaki, Yudai
Zaima, Masazumi
author_facet Yazawa, Takefumi
Hori, Tomohide
Yamamoto, Hidekazu
Harada, Hideki
Yamamoto, Michihiro
Yamada, Masahiro
Tani, Masaki
Sato, Asahi
Kamada, Yasuyuki
Tani, Ryotaro
Aoyama, Ryuhei
Sasaki, Yudai
Zaima, Masazumi
author_sort Yazawa, Takefumi
collection PubMed
description BACKGROUND: Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC). According to the 2017 Japanese treatment guideline for GC, a smaller number of liver metastases without unresectable factors may be an indication for liver resection (LR) with curability. The actual 5-year overall survival (OS) rate ranges from 0 to 0.37. AIM: To present the institutional indications for LR for LMGC and identify important factors for prognostic outcomes. METHODS: In total, 30 patients underwent LR for LMGC during a 14-year period, and we evaluated the clinical, surgical, and oncological findings. In all patients, radical surgery with intentional lymphadenectomy was performed for the primary GC. The median follow-up duration after the initial LR was 33.7 mo, and three patients with no recurrence died of causes unrelated to the LMGC. The OS and recurrence-free survival rates after the initial LR were assessed. RESULTS: Seventeen patients had metachronous LMGC. The initial LR achieved curability in 29 patients. Perioperative chemotherapy was introduced in 23 patients. The median greatest LMGC dimension was 30 mm, and the median number of LMGC was two. Twenty-two patients had unilobular LMGC. The 5-year OS and recurrence-free survival rates were 0.48 and 0.28, respectively. The median survival duration and recurrence-free duration after the initial LR were 16.8 and 8.6 mo, respectively. Twenty-one patients developed recurrence after the initial LR. Additional surgeries for recurrence were performed in nine patients, and these surgeries clearly prolonged the patients’ survival. Pathological serosal invasion was an independent predictor of a poor prognostic outcome after the initial LR. Aggressive LR may be indicated for carefully selected patients with LMGC. CONCLUSION: Our results of LR for LMGC seem acceptable. Additional surgeries for recurrence after the initial LR might prolong OS. Pathological serosal invasion is important for poor prognostic outcomes.
format Online
Article
Text
id pubmed-7667407
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-76674072020-11-27 Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience Yazawa, Takefumi Hori, Tomohide Yamamoto, Hidekazu Harada, Hideki Yamamoto, Michihiro Yamada, Masahiro Tani, Masaki Sato, Asahi Kamada, Yasuyuki Tani, Ryotaro Aoyama, Ryuhei Sasaki, Yudai Zaima, Masazumi World J Gastrointest Pharmacol Ther Retrospective Study BACKGROUND: Advanced gastric cancer (GC) with liver metastasis is often characterized by multiple and bilobular metastases and may also be associated with extrahepatic metastatic lesions. Hence, many physicians consider that radical surgeries are contraindicated for liver metastases from GC (LMGC). According to the 2017 Japanese treatment guideline for GC, a smaller number of liver metastases without unresectable factors may be an indication for liver resection (LR) with curability. The actual 5-year overall survival (OS) rate ranges from 0 to 0.37. AIM: To present the institutional indications for LR for LMGC and identify important factors for prognostic outcomes. METHODS: In total, 30 patients underwent LR for LMGC during a 14-year period, and we evaluated the clinical, surgical, and oncological findings. In all patients, radical surgery with intentional lymphadenectomy was performed for the primary GC. The median follow-up duration after the initial LR was 33.7 mo, and three patients with no recurrence died of causes unrelated to the LMGC. The OS and recurrence-free survival rates after the initial LR were assessed. RESULTS: Seventeen patients had metachronous LMGC. The initial LR achieved curability in 29 patients. Perioperative chemotherapy was introduced in 23 patients. The median greatest LMGC dimension was 30 mm, and the median number of LMGC was two. Twenty-two patients had unilobular LMGC. The 5-year OS and recurrence-free survival rates were 0.48 and 0.28, respectively. The median survival duration and recurrence-free duration after the initial LR were 16.8 and 8.6 mo, respectively. Twenty-one patients developed recurrence after the initial LR. Additional surgeries for recurrence were performed in nine patients, and these surgeries clearly prolonged the patients’ survival. Pathological serosal invasion was an independent predictor of a poor prognostic outcome after the initial LR. Aggressive LR may be indicated for carefully selected patients with LMGC. CONCLUSION: Our results of LR for LMGC seem acceptable. Additional surgeries for recurrence after the initial LR might prolong OS. Pathological serosal invasion is important for poor prognostic outcomes. Baishideng Publishing Group Inc 2020-11-08 2020-11-08 /pmc/articles/PMC7667407/ /pubmed/33251035 http://dx.doi.org/10.4292/wjgpt.v11.i5.110 Text en ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Yazawa, Takefumi
Hori, Tomohide
Yamamoto, Hidekazu
Harada, Hideki
Yamamoto, Michihiro
Yamada, Masahiro
Tani, Masaki
Sato, Asahi
Kamada, Yasuyuki
Tani, Ryotaro
Aoyama, Ryuhei
Sasaki, Yudai
Zaima, Masazumi
Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience
title Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience
title_full Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience
title_fullStr Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience
title_full_unstemmed Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience
title_short Do liver metastases from gastric cancer contraindicate aggressive surgical resection? A 14-year single-center experience
title_sort do liver metastases from gastric cancer contraindicate aggressive surgical resection? a 14-year single-center experience
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667407/
https://www.ncbi.nlm.nih.gov/pubmed/33251035
http://dx.doi.org/10.4292/wjgpt.v11.i5.110
work_keys_str_mv AT yazawatakefumi dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT horitomohide dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT yamamotohidekazu dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT haradahideki dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT yamamotomichihiro dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT yamadamasahiro dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT tanimasaki dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT satoasahi dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT kamadayasuyuki dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT taniryotaro dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT aoyamaryuhei dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT sasakiyudai dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience
AT zaimamasazumi dolivermetastasesfromgastriccancercontraindicateaggressivesurgicalresectiona14yearsinglecenterexperience